Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer

(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and pertuzumab (Perjeta) maintenance…

Source link : https://www.medpagetoday.com/meetingcoverage/sabcsvideopearls/119134

Author :

Publish date : 2025-12-22 17:56:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer

Next-Gen Oral SERD Cuts Recurrence Risk in Early Breast Cancer

Is Art the Missing Tool From Modern Healthcare?

Related Posts

Using the EHR to Deprescribe Risky Meds; Knee Braces for Osteoarthritis

Medical Education Must Go Beyond Individual Pathology

Colorectal Cancer Is Rising in Younger Adults. Who’s At Risk and What Are the Signs?

What These 5 Women Want You to Know

Stroke survivors trial new at-home tech: ‘It’s given me my freedom back’

These Five Diets Are Linked to a Lower Death Risk

Using the EHR to Deprescribe Risky Meds; Knee Braces for Osteoarthritis

Medical Education Must Go Beyond Individual Pathology

Colorectal Cancer Is Rising in Younger Adults. Who’s At Risk and What Are the Signs?

What These 5 Women Want You to Know

Stroke survivors trial new at-home tech: ‘It’s given me my freedom back’

These Five Diets Are Linked to a Lower Death Risk

Alzheimer’s Dementia Risk Nearly 40% Lower With Lifelong Learning

State, Federal Lawmakers Aim to Bar PBMs From Owning Pharmacies

Categories

Archives